Moderna stock tanks on COVID vaccine delivery slowdown

Due to the delays and prioritization of low-income countries, Moderna anticipates fiscal year 2021 product sales between $15B and $18B, down from previous guidance of $20 billion.

The Bank also expects the economy to grow more than previously forecast this year, although uncertainties remain because of the Iran war. f...
0 comments:
Post a Comment